-
Human medicines European public assessment report (EPAR): Emend, aprepitant, Date of authorisation: 11/11/2003, Revision: 31, Status: Authorised
08 Mar 2024 16:26 GMT
… They compared the effectiveness of Emend, taken in combination with … studies showed that adding Emend to the standard combination was … no need for any other medication to control nausea and … children given ondansetron alone. Emend was also effective in the …
-
Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Short Interest Down 15.8% in September
14 Oct 2023 16:29 GMT
… subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It … Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous … ' ratings for Ono Pharmaceutical and related companies with MarketBeat …
-
Non-Compliance Letters under 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act
13 Sep 2023 02:34 GMT
… Sharp & Dohme Corp.
Emend (aprepitant) capsules
11… not paid
Bayer Healthcare Pharmaceuticals, Inc.
Eovist ( … /14)
The Medicines Company
Cleviprex (clevidipine) … US, Inc. (formerly Luitpold Pharmaceuticals, Inc.)
Sprix (ketorolac tromethamine …
-
Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Sees Significant Drop in Short Interest
14 Sep 2023 19:10 GMT
… subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It … Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous … ' ratings for Ono Pharmaceutical and related companies with MarketBeat …
-
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
12 Mar 2024 23:27 GMT
… a commercial-stage biotechnology company, today announced … active ingredient in EMEND® capsules. Aprepitant ( … chemotherapy). The FDA-approved dosing administration … medical care. Our advanced science, patented technologies, and innovative approach to drug …
-
Ono Pharmaceutical (OTCMKTS:OPHLY) Trading Up 1.1%
08 Aug 2023 07:13 GMT
… Latest Stock Report on Ono Pharmaceutical
Ono Pharmaceutical Trading Up 1.1 … , produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It … for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules …
-
CINV Existing and Pipeline Drugs Market to reach US$ 3.2 billion in 2031, expanding at a CAGR of 5.8%: TMR Report
18 Jul 2023 12:30 GMT
… pipeline drugs market.
Rolapitant received FDA … clinical trials, pipeline medications outperformed conventional drugs in … by cancer medicine treatment (chemotherapy). As a … pharmaceuticals including Aloxi and Emend, the introduction of CINV pipeline drugs …
-
FY2024 Earnings Estimate for Ono Pharmaceutical Co., Ltd. Issued By Jefferies Financial Group (OTCMKTS:OPHLF)
05 Jan 2023 06:54 GMT
… 25.03.
About Ono Pharmaceutical
(Get Rating)
Ono Pharmaceutical Co, Ltd., together … , produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It … the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules …
-
FDA Action Alert: Obseva, bluebird bio and Heron
12 Sep 2022 19:08 GMT
… of positive 24-week treatment data from both trials and supportive data … the U.S.
EMEND was approved by the FDA for oral dosing … surgery. In a Phase I trial, HTX-019 32mg as a … with activity similar to two-drug combinations," said Barry Quart …
-
Chemotheraphy Induced Nausea and Vomitting Drugs Market Forecast | Projected To Garner Significant Revenues By 2031
02 Sep 2022 12:20 GMT
… Pharmaceuticals
OPKO Health
Orchid Healthcare
Worldwide Chemotheraphy Induced Nausea and Vomitting Drugs … )
Emend (aprepitant)
Akynzeo (netupitant-palonosetron)
Worldwide Chemotheraphy Induced Nausea and Vomitting Drugs …